IRWD Ironwood Pharmaceuticals Inc.

9.87
-0.22  -2%
Previous Close 10.09
Open 9.79
Price To Book -16.73
Market Cap 1,561,502,221
Shares 158,206,912
Volume 1,618,748
Short Ratio
Av. Daily Volume 1,983,889
Stock charts supplied by TradingView

NewsSee all news

  1. Ironwood Pharmaceuticals Provides Update on Impact of COVID-19

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today provided an update on certain impacts of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus

  2. Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology

    – Data showed improvement in both heartburn and regurgitation symptoms and further demonstrated the role of bile acid in refractory gastroesophageal reflux disease (GERD) – – IW-3718 is currently in two Phase III

  3. Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in March: Cowen and Company 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 8:00 a.m. ET

  4. Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 9:30 a.m. Eastern Time at the Lotte New York

  5. Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

    –2019 revenue of $428 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue– –GAAP net income from continuing operations of $59 million and adjusted EBITDA from continuing operations of $148

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced August 21, 2017.
DUZALLO (LESINURAD AND ALLOPURINOL)
Hyperuricemia associated with gout
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data met all endpoints - June 18, 2019.
Linaclotide
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
IW-9179
Gastroparesis
Phase 3 data no longer due 2H 2020. Assessing COVID-19 situation and plans to provide an update on timing when it has more clarity.
IW-3718
Gastroesophageal reflux disease (GERD)
No additional trials planned.
IW-1701
Achalasia
Phase 2 top-line data due mid-2020.
MD-7246
Irritable Bowel Syndrome

Latest News

  1. Ironwood Pharmaceuticals Provides Update on Impact of COVID-19

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today provided an update on certain impacts of COVID-19 on its business and the actions it is taking to mitigate the spread of this virus

  2. Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology

    – Data showed improvement in both heartburn and regurgitation symptoms and further demonstrated the role of bile acid in refractory gastroesophageal reflux disease (GERD) – – IW-3718 is currently in two Phase III

  3. Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in March: Cowen and Company 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 8:00 a.m. ET

  4. Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 9:30 a.m. Eastern Time at the Lotte New York

  5. Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

    –2019 revenue of $428 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue– –GAAP net income from continuing operations of $59 million and adjusted EBITDA from continuing operations of $148

  6. Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its fourth quarter and full- year 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 13, 2020.

  7. Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation

    – Settlement with Teva represents final outstanding LINZESS patent litigation – – The earliest licensed entry of any generic linaclotide 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc.

  8. Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Allergan plc (NYSE:AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in response to Sandoz's

  9. Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 4:00 p.m. Pacific Time/ 7:00 p.m. Eastern Time at the

  10. Dermira Elects Halley E. Gilbert to its Board of Directors

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  11. Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the 28th Annual Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 4:10 p.m. Mountain Standard Time (6:10 p.m. Eastern

  12. Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance

    – Total revenue of $131 million, driven primarily by LINZESS® (linaclotide) U.S. collaboration revenue of $85 million and ex-U.S. license and milestone revenue of $42 million – – $21 million in GAAP net income from

  13. Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

    – Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent – – AstraZeneca obtains

  14. Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present corporate updates at two upcoming investor conferences in September: 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at 2:25 p.m. ET at